Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 38Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 10Neoplasm Metastasis 7Hodgkin Disease 6Recurrence 4Neoplasms 4Uterine Cervical Neoplasms 3Sarcoma 2Rhabdomyosarcoma 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Carcinoma 2Breast Neoplasms, Male 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Pleural Effusion, Malignant 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non - Small Cell Lung Cancer NSCLC 1Neuroendocrine Tumors 1Neuralgia 1Metatropic dwarfism 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Locally Advanced Non-Small Cell Lung Cancer 1Lethal Congenital Contracture Syndrome 2 1Glioma 1

Interventions

seribantumab 2zenocutuzumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lethal Congenital Contracture Syndrome 2 × Vinorelbine × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡